Gilead’s lenacapavir has been on the market since 2022, when it was approved in the U.S. as Sunlenca for twice-yearly ...

Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer (NSCLC) has narrowed.

After dodging a layer of U.S. scrutiny thus far, Chinese CDMO WuXi AppTec is back in the government’s crosshairs. The company is now listed on the U.S. Department of War’s newly updated roster of ...

The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing ...

It’s a sign of the times that this year’s American Diabetes Association (ADA) Scientific Sessions meeting in New Orleans ...

For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first ...

Twenty-six years of chasing New York City sex crimes as the face of “Law & Order: Special Victims Unit” has prepared ...

The new expansion covers all patients 6 and older, regardless of their inhibitor status. The new nod also opens up the ...

In the persistence and adherence analysis, which looked at 28 studies including 267,542 patients, Amgen found that 69% of ...

Eli Lilly and Boehringer Ingelheim are cutting back on planned investments in Germany in response to a new government ...

Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised ...

The FDA is going forward with an investigation into the safety of the abortion pill mifepristone, an initiative which could ...